GPT and metabolic dysfunction-associated steatotic liver disease: In conclusion, this PS-matched comparative real-world study showed that the addition of SGLT2is decreased body weight and ALT levels significantly compared with other OADs in T2DM patients with NAFLD on metformin therapy.